Effect of riluzole on weight in short-term and long-term survivors of amyotrophic lateral sclerosis

References

• Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085.
   PubMed Web of Science ®Google Scholar
• Chio A, Logroscino G, Hardiman O, Swingler S, Mitchell D, Traynor BG. and EURALS Consortium. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009;10:310–23.
   PubMed Web of Science ®Google Scholar
• Scagnelli CN, Howard DB, Bromberg MB, Kasarskis EJ, Matthews DE, Mitsumoto HM, et al., ALS Nutrition-NIPPV Study Group. Hydration measured by doubly labeled water in ALS and its effects on survival. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:220–31.
   PubMed Web of Science ®Google Scholar
• Marin B, Desport JC, Kajeu P, Jesus P, Nicolaud B, Nicol M, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2011;82:628–34.
   PubMed Web of Science ®Google Scholar
• Moglia C, Calvo A, Grassano M, Canosa A, Manera U, D'Ovidio F, et al. Piemonte and Valle d’Aosta Register for ALS (PARALS). Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry. 2019;90:666–73.
   PubMed Web of Science ®Google Scholar
• Tandan R, Waheed W, Scagnelli C. Nutritional consequences of amyotrophic lateral sclerosis. In: Preedy VR, Patel VB, eds. Handbook of famine, starvation, and nutrient deprivation: from biology to policy. London: Springer; 2019. Chapter 108.
   Google Scholar
• Jawaid A, Murthy S, Wilson AM, Qureshi SU, Amro MJ, Wheaton M, Simpson E, et al. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph Lateral Scler. 2010;11:542–8.
   PubMed Web of Science ®Google Scholar
• Limousin N, Blasco H, Corcia P, Gordon PH, De Toffol B, Andres C, et al. Malnutrition at the time of diagnosis is associated with a shorter disease duration in ALS. J Neurol Sci. 2010;297:36–9.
   PubMed Web of Science ®Google Scholar
• Chiò A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology 2020;167:107986.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. and the ALS/Riluzole Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study GroupN Engl J Med. 1994;330:585–91.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Meininger V, Leigh PN, Guillet P, Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425–31.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;3:CD001447.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V, Riluzole/ALS Study Group II. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249:609–15.
   PubMed Web of Science ®Google Scholar
• Hinchcliffe M, Smith A. Riluzole: Real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis. 2017;7:61–70.
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Malerba SA, Beghi E, Fini N, Fasano A, Zucchi E, et al., ERRALS Group. Riluzole and other prognostic factors in ALS: a population-based registry study in Italy. J Neurol. 2018;265:817–27.
   PubMed Web of Science ®Google Scholar
• Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010;17:1942–59.
   PubMed Web of Science ®Google Scholar
• Geevasinga N, Menon P, Ng K, Van Den Bos M, Byth K, Kiernan MC, et al. Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:580–8.
   PubMed Web of Science ®Google Scholar
• Del Signore SJ, Amante DJ, Kim J, Stack EC, Goodrich S, Cormier K, et al. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph Lateral Scler. 2009;10:85–94.
   PubMed Web of Science ®Google Scholar
• Schiefer J, Landwehrmeyer G, Luesse H-G, Sprunken A, Puls C, Milkereit A, et al. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington’s disease. Mov Disord. 2002;17:748–57.
   PubMed Web of Science ®Google Scholar
• Toklu HZ, Uysal MK, Kabasakal L, Sirvanci S, Ercan F, Kaya M. The effects of Riluzole on neurological, brain biochemical, and histological changes in early and late term of sepsis in rats. J Surg Res. 2009;152:238–48.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265–7.
   PubMed Web of Science ®Google Scholar
• Zou G. A Modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702–6.
   PubMed Web of Science ®Google Scholar
• Boylan K, Levine T, Lomen-Hoerth C, Lyon M, Maginnis K, Callas P, et al., ALS Center Cost Evaluation W/Standards & Satisfaction (Access) Consortium. Prospective study of cost of care at multidisciplinary ALS centers adhering to American Academy of Neurology (AAN) ALS practice parameters. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17:119–27.
   PubMed Web of Science ®Google Scholar
• Cetin H, Rath J, Fuzi J, Reichardt B, Fulop G, Koppi S, et al. Epidemiology of amyotrophic lateral sclerosis and effect of riluzole on disease course. Neuroepidemiology 2015;44:6–15.
   PubMed Web of Science ®Google Scholar
• Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998;55:526–8.
   PubMed Web of Science ®Google Scholar
• Fang T, Al Khleifat A, Meurgey J-H, Jones A, Leigh PN, Bensimon G, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet. 2018;17:416–22.
   Web of Science ®Google Scholar
• Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem. 2006;98:641–53.
   PubMed Web of Science ®Google Scholar
• Petrus P, Lecoutre S, Dollet L, Wiel C, Sulen A, Gao H, et al. Glutamine links obesity to inflammation in human white adipose tissue. Cell Metab. 2020;31:375–90.e11.
   PubMed Web of Science ®Google Scholar
• Abboud K, Reis S, Martelli M, Zordão O, Tannihão F, de Souza A, et al. Oral glutamine supplementation reduces obesity, pro-inflammatory markers, and improves insulin sensitivity in DIO Wistar rats and reduces waist circumference in overweight and obese humans. Nutrients 2019;11:536.
   PubMed Web of Science ®Google Scholar
• Sedgwick P. Bias in observational study designs: cross sectional studies. BMJ. 2015;350:h1286.
   PubMed Web of Science ®Google Scholar
• Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci. 2001;191:3–9.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al., for the SLAP registry. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in Southern Italy. Eur J Neurol. 2007;14:262–8.
   PubMed Web of Science ®Google Scholar
• Lee CT, Chiu YW, Wang KC, Hwang CS, Lin KH, Lee IT, etal. Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan. J Epidemiol. 2013;23:35–40.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Belden DS, Roelke K, et al. Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS) – motor neuron disease (MND) patients with disease onset before and since 1996 is identical: a clinic-based epidemiological study. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:60–1.
   Google Scholar